Vertex Pharmaceuticals stock forecast
Vertex Pharmaceuticals (VX1) Stock Forecast & Price Target
VX1 Analyst Ratings
VX1 Stock 12 Month Forecast
Average Price Target
€552.92▲(13.49% Upside)Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Tazeen Ahmad | Bank of America Securities | ― | buy | ― | Reiterated | 11/12/26 | ||
| Michael Yee | UBS | €554.23→€576.75 | buy | 18.38%Upside | Reiterated | 11/04/26 | ||
| Ananda Ghosh | H.C. Wainwright | €577.66 | buy | 18.57%Upside | Reiterated | 11/04/26 | ||
| Eliana Merle | Barclays | €556.03→€564.14 | buy | 15.79%Upside | Reiterated | 11/04/26 | ||
| Naz Rahman | Maxim Group | €518.18→€558.73 | buy | 14.68%Upside | Reiterated | 11/04/26 | ||
| Geoff Meacham | Citi | €527.19 | buy | 8.21%Upside | Reiterated | 11/03/26 | ||
| Jessica Fye | J.P. Morgan | €504.66→€513.67 | buy | 5.43%Upside | Assigned | 11/03/26 | ||
| Salveen Richter | Goldman Sachs | €589.37→€653.36 | buy | 34.10%Upside | Assigned | 11/03/26 | ||
| Terence Flynn | Morgan Stanley | €599.28→€594.78 | buy | 22.08%Upside | Assigned | 11/03/26 | ||
| Paul Matteis | Stifel Nicolaus | €450.59→€507.36 | hold | 4.14%Upside | Reiterated | 11/03/26 | ||
| Louise Chen | Scotiabank | €594.78 | buy | 22.08%Upside | Assigned | 11/03/26 | ||
| Phil Nadeau | TD Cowen | €495.65→€518.18 | buy | 6.36%Upside | Reiterated | 11/03/26 | ||
| Evan Seigerman | BMO Capital | €540.71→€558.73 | buy | 14.68%Upside | Reiterated | 11/03/26 | ||
| Mohit Bansal | Wells Fargo | €495.65→€585.77 | buy | 20.23%Upside | Reiterated | 11/02/26 | ||
| Carter Gould | Cantor Fitzgerald | €536.20→€557.83 | buy | 14.50%Upside | Reiterated | 11/02/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Tazeen AhmadBank of America Securities | BuyReiterated | 11/12/26 | ― | ||
| Michael YeeUBS | BuyReiterated€554.23→€576.75 | 11/04/26 | 18.38%Upside | ||
| Ananda GhoshH.C. Wainwright | BuyReiterated€577.66 | 11/04/26 | 18.57%Upside | ||
| Eliana MerleBarclays | BuyReiterated€556.03→€564.14 | 11/04/26 | 15.79%Upside | ||
| Naz RahmanMaxim Group | BuyReiterated€518.18→€558.73 | 11/04/26 | 14.68%Upside | ||
| Geoff MeachamCiti | BuyReiterated€527.19 | 11/03/26 | 8.21%Upside | ||
| Jessica FyeJ.P. Morgan | BuyAssigned€504.66→€513.67 | 11/03/26 | 5.43%Upside | ||
| Salveen RichterGoldman Sachs | BuyAssigned€589.37→€653.36 | 11/03/26 | 34.10%Upside | ||
| Terence FlynnMorgan Stanley | BuyAssigned€599.28→€594.78 | 11/03/26 | 22.08%Upside | ||
| Paul MatteisStifel Nicolaus | HoldReiterated€450.59→€507.36 | 11/03/26 | 4.14%Upside | ||
| Louise ChenScotiabank | BuyAssigned€594.78 | 11/03/26 | 22.08%Upside | ||
| Phil NadeauTD Cowen | BuyReiterated€495.65→€518.18 | 11/03/26 | 6.36%Upside | ||
| Evan SeigermanBMO Capital | BuyReiterated€540.71→€558.73 | 11/03/26 | 14.68%Upside | ||
| Mohit BansalWells Fargo | BuyReiterated€495.65→€585.77 | 11/02/26 | 20.23%Upside | ||
| Carter GouldCantor Fitzgerald | BuyReiterated€536.20→€557.83 | 11/02/26 | 14.50%Upside |
Best Analysts Covering Vertex Pharmaceuticals
Copying Naz Rahman's trades and holding each position for 3 Months would result in 87.50% of your transactions generating a profit, with an average return of +8.28% per trade.
Copying Naz Rahman's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +18.51% per trade.
Copying Geoff Meacham's trades and holding each position for 2 Years would result in 97.50% of your transactions generating a profit, with an average return of +24.79% per trade.
VX1 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 50 | 59 | 70 | 62 | 53 |
| Hold | 9 | 9 | 9 | 6 | 3 |
| Sell | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 60 | 69 | 80 | 68 | 56 |
In the current month, VX1 has received 53 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. VX1 average Analyst price target in the past 3 months is 552.92.
VX1 Financial Forecast
VX1 Earnings Forecast
Next quarter’s earnings estimate for VX1 is EUR 3.81 with a range of EUR 3.44 to EUR 4.90. The previous quarter’s EPS was EUR 4.32. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
VX1 Sales Forecast
Next quarter’s sales forecast for VX1 is EUR 3.17B with a range of EUR 3.10B to EUR 3.26B. The previous quarter’s sales results were EUR 3.12B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

